Commerce Bank Has $1.24 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Commerce Bank cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.1% during the third quarter, Holdings Channel reports. The institutional investor owned 4,522 shares of the biopharmaceutical company’s stock after selling 95 shares during the quarter. Commerce Bank’s holdings in Alnylam Pharmaceuticals were worth $1,244,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. PNC Financial Services Group Inc. grew its position in Alnylam Pharmaceuticals by 1.2% during the third quarter. PNC Financial Services Group Inc. now owns 12,543 shares of the biopharmaceutical company’s stock worth $3,450,000 after buying an additional 144 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new position in Alnylam Pharmaceuticals during the third quarter worth about $902,000. Banque Cantonale Vaudoise bought a new position in Alnylam Pharmaceuticals during the third quarter worth about $1,529,000. Pathstone Holdings LLC lifted its stake in Alnylam Pharmaceuticals by 11.2% during the third quarter. Pathstone Holdings LLC now owns 6,249 shares of the biopharmaceutical company’s stock worth $1,719,000 after purchasing an additional 629 shares during the period. Finally, TrinityPoint Wealth LLC bought a new position in Alnylam Pharmaceuticals during the third quarter worth about $200,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $244.89 on Monday. The company has a 50 day moving average price of $273.13 and a 200 day moving average price of $238.67. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The stock has a market capitalization of $31.59 billion, a PE ratio of -93.47 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. During the same period in the previous year, the company earned $1.15 earnings per share. The business’s revenue for the quarter was down 33.3% on a year-over-year basis. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.22 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ALNY. Raymond James raised their price target on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Needham & Company LLC restated a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Citigroup raised their price target on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Royal Bank of Canada restated an “outperform” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. lifted their target price on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a research note on Monday, August 26th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $298.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.